Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model

Isomalto oligosaccharide sulfate inhibits tumor growth and metastasis of hepatocellular carcinoma in nude mice

(2011) Chun-Li Xiao et al.   BMC CANCER

Identification of transaldolase as a novel serum biomarker for hepatocellular carcinoma metastasis using xenografted mouse model and clinic samples

(2011) Cun Wang et al.   CANCER LETTERS

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

(2011) Irene M Ghobrial et al.   LANCET ONCOLOGY

Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells

(2010) Steffen Wedel et al.   CANCER LETTERS

Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling

(2010) Xin He et al.   CANCER LETTERS

Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma

(2010) B. Boozari et al.   GUT

An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma

(2010) George P. Kim et al.   INVESTIGATIONAL NEW DRUGS

Rapamycin Regulates Endothelial Cell Migration through Regulation of the Cyclin-dependent Kinase Inhibitor p27Kip1

(2010) Stephanie C. Moss et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway byNanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma

(2010) Diana Cirstea et al.   MOLECULAR CANCER THERAPEUTICS

CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells

(2010) K-F Chen et al.   ONCOGENE

mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice

(2009) Guiqin Hou et al.   CANCER LETTERS

Rapamycin inhibits lung metastasis of B16 melanoma cells through down-regulating alphav integrin expression and up-regulating apoptosis signaling

(2009) Zhuoshun Yang et al.   CANCER SCIENCE

Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway

(2009) Kuen-Feng Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation

(2009) Kuen-Feng Chen et al.   JOURNAL OF HEPATOLOGY

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population

(2008) Thomas Yau et al.   CANCER

Down-regulation of Phospho-Akt Is a Major Molecular Determinant of Bortezomib-Induced Apoptosis in Hepatocellular Carcinoma Cells

(2008) K.-F. Chen et al.   CANCER RESEARCH

Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma

(2008) Z. Wang et al.   CLINICAL CANCER RESEARCH

Biological characteristics of fluorescent protein-expressing human hepatocellular carcinoma xenograft model in nude mice

(2008) Bi-Wei Yang et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice

(2008) Sven A. Lang et al.   HEPATOLOGY

Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma

(2008) Zheng Wang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE